XBI

SPDR S&P Biotech ETF (XBI) | Rumor.io

SPDR S&P Biotech ETF

XBI

Attention (50-day avg)0.45%

Attention rank (50-day avg)#47

Bullish sentiment (50-day avg)75%

Price to earnings ratio0

Net assets0

Expense ratio0%

Social

What share of all ETF conversation is about XBI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.42% +0.08	0.45% +0.14	0.36% -0.17	0.08% +0.04

Sep 29

$XBI is turning up, with a 3.7% gain needed to surpass $9, and a potential tailwind from the biotech ETF's performance.
$XBI's performance is mirroring the bio index move, and some investors are considering futures exposure to gain $SPY-like returns.
$XBI is extending wave I with strong momentum and controlled pullbacks, maintaining control as wave ((4)) stays dormant.

Generated by AI

Sentiment

Of the messages about XBI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	93.02% +8.28	60.8% -20.49	71.91% -7.2	83.43% +7.46
Bearish	6.98% -8.28	39.2% +20.49	28.09% +7.2	16.57% -7.46

Bullish· Sep 28

$XBI has seen a significant increase in volume, with over 6.25 million shares traded in a single session, indicating growing interest in the biotech sector.
The biotech sector is poised for growth due to catalysts such as the patent cliff, AI in drug discovery, aging population, and drug-pricing clarity, making it an attractive investment opportunity.
The sector is experiencing a "tailwind" with companies like $XBI and $GRI showing promise, and investors are rotating into biotech, particularly those with a history of seeking explosive returns.

Bearish· Sep 24

$XBI is experiencing a significant price drop, down 15% from its 52-week high, which may indicate a bear market.
The biotech sector is vulnerable to market downturns, with speculative biotech stocks like $XBI often experiencing a 25% drop after a perceived bottom, making it a high-risk investment.
Rising interest rates and inflation, partly attributed to Trump's actions, are causing a crash in vulnerable sectors like biotech, with $XBI not reflecting this trend despite other tickers being 50% below their 52-week highs.

Generated by AI

Topics

Of the messages about XBI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	91.51%	89.86%	95.26%
Macro	0%	8.49%	10.14%	4.74%

Macro· Mar 31

The SPDR S&P Biotech ETF (XBI) has seen a significant increase, up 6.4%, with the biotech sector experiencing a surge in M&A activity.
The ETF's performance is being driven by the ongoing M&A activity in the biotech space, with several takeovers and acquisitions contributing to the sector's growth.
The market's weakness is expected to keep a lid on the XBI, but the recent big acquisitions are bringing excitement to the entire sector, and the ETF is poised to continue its upward trend.

Technical Analysis· Sep 29

$XBI is turning up, with a 3.7% gain needed to surpass $9, which could provide a tailwind until the next trial update.
$XBI's volume was low early in the day yesterday, but picked up in the afternoon, with 10.38 million shares traded, a 17.7% decrease from the typical daily volume over the past 6 months.
$XBI is still in a 10% correction mode from its high of $170, but can quickly change between now and the election, potentially returning to a bear market.

Generated by AI

Community

Of the messages about XBI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.1%	81.6%	89.87%	85.91%
Newcomers	16.9%	18.4%	10.13%	14.09%

Regulars· Sep 29

$XBI is turning up, and the author expects a tailwind from this trend, along with a potential breakout above $9.
The author is considering buying $XBI and $SPY exposure through futures on margin, and is taking notes on this strategy, which is being popularized by others.
$XBI is technically still in a 10% correction mode from its high of $170, but the author notes that this can change quickly, and that the sector could be pulled back into a bear market.

Newcomers· Sep 28

Newcomers are drawn to the $XBI ETF due to its high potential for big gains, but are also aware of its history of brutal crashes.
Investors are focusing on the $XBI ETF's holdings, such as Amgen, and the differences in weighting between the $XBI and $IBB ETFs.
The biotech sector is experiencing a strong tailwind due to factors like patent cliffs, AI in drug discovery, aging population, and faster FDA approval processes, with ETFs like $XBI and $IBB offering basket approaches.

Generated by AI

News

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

1d agoYahoo Finance Singapore

Biotech ETF XBI Hits a Rate Wall as 40+ Catalysts Approach - State Street SPDR S&P Biotech ETF (ARCA:XBI)

B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.

4d agoBenzinga

Economy Grew 63%, 30-Year Treasury Lost 45% Since 2020 - State Street SPDR S&P Biotech ETF (ARCA:XBI), iS

Over six years, U.S. nominal GDP rose 63% while the 30-year Treasury fell 60%. Are investors positioned for a surge in stocks and yields?

4d agoBenzinga

Biotech: The Party's Over, The Top Is In (NYSEARCA:XBI)

XBI may have peaked after a 60% rally as tailwinds fade, equity supply hits cycle highs, and momentum rolls over. Click to read more about XBI's sell rating.

5d agoSeeking Alpha

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? | The Motley Fool

VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

7d agoThe Motley Fool

Is State Street SPDR S&P Transportation ETF (XTN) a Strong ETF Right Now?

Smart Beta ETF report for XTN

8d agoYahoo Finance

Also Discussed

Investors talking about XBI also mention

#	Name	Attention
1	iShares Biotechnology ETFIBB	0.01%0
2	Direxion Daily S&P Biotech Bull 3X SharesLABU	0.01%+0.01
3	Direxion Daily S&P Biotech Bear 3X SharesLABD	0.01%+0.01
4	VanEck Biotech ETFBBH	0%new
5	ProShares Ultra Nasdaq BiotechnologyBIB	0%new
6	Biogen IncBIIB	0%-0.01
7	VanEck Pharmaceutical ETFPPH	0%new
8	Invesco S&P 500 Equal Weight Health Care ETFRSPH	0%new
9	iShares U.S. Medical Devices ETFIHI	0%-0.02
10	Ionis Pharmaceuticals, Inc.IONS	0%new

SPDR S&P Biotech ETF

SPDR S&P Biotech ETF is an exchange-traded fund designed to track an equal-weighted index of U.S. biotechnology stocks. The fund gives investors broad exposure to the biotechnology segment of the healthcare market, with holdings that typically include companies involved in drug discovery, genetic research, therapeutic development, diagnostics, and advanced life sciences tools. Its equal-weighted approach reduces concentration in the largest names and provides more balanced representation across smaller and mid-sized biotech companies. SPDR S&P Biotech ETF is used as a diversified vehicle for gaining exposure to a sector known for innovation, scientific research, and product development across human health and medical technology. Managed by State Street, the fund serves market participants looking for targeted access to the biotech industry through a single pooled portfolio.

Location

United States

Social

What share of all ETF conversation is about XBI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.42% +0.08	0.45% +0.14	0.36% -0.17	0.08% +0.04

Sep 29

$XBI is turning up, with a 3.7% gain needed to surpass $9, and a potential tailwind from the biotech ETF's performance.
$XBI's performance is mirroring the bio index move, and some investors are considering futures exposure to gain $SPY-like returns.
$XBI is extending wave I with strong momentum and controlled pullbacks, maintaining control as wave ((4)) stays dormant.

Generated by AI

Sentiment

Of the messages about XBI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	93.02% +8.28	60.8% -20.49	71.91% -7.2	83.43% +7.46
Bearish	6.98% -8.28	39.2% +20.49	28.09% +7.2	16.57% -7.46

Bullish· Sep 28

$XBI has seen a significant increase in volume, with over 6.25 million shares traded in a single session, indicating growing interest in the biotech sector.
The biotech sector is poised for growth due to catalysts such as the patent cliff, AI in drug discovery, aging population, and drug-pricing clarity, making it an attractive investment opportunity.
The sector is experiencing a "tailwind" with companies like $XBI and $GRI showing promise, and investors are rotating into biotech, particularly those with a history of seeking explosive returns.

Bearish· Sep 24

$XBI is experiencing a significant price drop, down 15% from its 52-week high, which may indicate a bear market.
The biotech sector is vulnerable to market downturns, with speculative biotech stocks like $XBI often experiencing a 25% drop after a perceived bottom, making it a high-risk investment.
Rising interest rates and inflation, partly attributed to Trump's actions, are causing a crash in vulnerable sectors like biotech, with $XBI not reflecting this trend despite other tickers being 50% below their 52-week highs.

Generated by AI

Topics

Of the messages about XBI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	91.51%	89.86%	95.26%
Macro	0%	8.49%	10.14%	4.74%

Macro· Mar 31

The SPDR S&P Biotech ETF (XBI) has seen a significant increase, up 6.4%, with the biotech sector experiencing a surge in M&A activity.
The ETF's performance is being driven by the ongoing M&A activity in the biotech space, with several takeovers and acquisitions contributing to the sector's growth.
The market's weakness is expected to keep a lid on the XBI, but the recent big acquisitions are bringing excitement to the entire sector, and the ETF is poised to continue its upward trend.

Technical Analysis· Sep 29

$XBI is turning up, with a 3.7% gain needed to surpass $9, which could provide a tailwind until the next trial update.
$XBI's volume was low early in the day yesterday, but picked up in the afternoon, with 10.38 million shares traded, a 17.7% decrease from the typical daily volume over the past 6 months.
$XBI is still in a 10% correction mode from its high of $170, but can quickly change between now and the election, potentially returning to a bear market.

Generated by AI

Community

Of the messages about XBI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.1%	81.6%	89.87%	85.91%
Newcomers	16.9%	18.4%	10.13%	14.09%

Regulars· Sep 29

$XBI is turning up, and the author expects a tailwind from this trend, along with a potential breakout above $9.
The author is considering buying $XBI and $SPY exposure through futures on margin, and is taking notes on this strategy, which is being popularized by others.
$XBI is technically still in a 10% correction mode from its high of $170, but the author notes that this can change quickly, and that the sector could be pulled back into a bear market.

Newcomers· Sep 28

Newcomers are drawn to the $XBI ETF due to its high potential for big gains, but are also aware of its history of brutal crashes.
Investors are focusing on the $XBI ETF's holdings, such as Amgen, and the differences in weighting between the $XBI and $IBB ETFs.
The biotech sector is experiencing a strong tailwind due to factors like patent cliffs, AI in drug discovery, aging population, and faster FDA approval processes, with ETFs like $XBI and $IBB offering basket approaches.

Generated by AI

SPDR S&P Biotech ETF

Social

Sep 29

Bullish· Sep 28

Bearish· Sep 24

Macro· Mar 31

Technical Analysis· Sep 29

Regulars· Sep 29

Newcomers· Sep 28

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Biotech ETF XBI Hits a Rate Wall as 40+ Catalysts Approach - State Street SPDR S&P Biotech ETF (ARCA:XBI)

Economy Grew 63%, 30-Year Treasury Lost 45% Since 2020 - State Street SPDR S&P Biotech ETF (ARCA:XBI), iS

Biotech: The Party's Over, The Top Is In (NYSEARCA:XBI)

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? | The Motley Fool

Is State Street SPDR S&P Transportation ETF (XTN) a Strong ETF Right Now?

Also Discussed

SPDR S&P Biotech ETF

Company Information

Location

Social

Sep 29

Bullish· Sep 28

Bearish· Sep 24

Macro· Mar 31

Technical Analysis· Sep 29

Regulars· Sep 29

Newcomers· Sep 28

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Biotech ETF XBI Hits a Rate Wall as 40+ Catalysts Approach - State Street SPDR S&P Biotech ETF (ARCA:XBI)

Economy Grew 63%, 30-Year Treasury Lost 45% Since 2020 - State Street SPDR S&P Biotech ETF (ARCA:XBI), iS

Biotech: The Party's Over, The Top Is In (NYSEARCA:XBI)

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? | The Motley Fool

Is State Street SPDR S&P Transportation ETF (XTN) a Strong ETF Right Now?

Also Discussed